Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.
MedPage Today on MSN9h
High Price of GLP-1 Agents Tip Cost-Benefit Scale UnfavorablyTirzepatide and semaglutide were associated with larger QALY gains (incremental gains of 0.35 and 0.25 over lifestyle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback